Posts in Category: drug pricing

Presidential Budget Proposes 340B Savings Usage Records, Covered Entity User Fees, and Expanded HRSA Authority

On February 10, 2020, the White House released the
Administration’s budget proposal for Fiscal Year (FY) 2021, A
Budget For America’s Future. This document summarizes the President’s
recommendations

20 Feb 2020

HRSA Audit Results Reveal Manufacturer Overcharges

On January 28, 2020, HRSA posted results
of its 340B Program audit of four pharmaceutical manufacturers in fiscal year 2019.  Three of the four
audited manufacturers were

14 Feb 2020

GAO Issues Report Criticizing HHS’ Oversight of 340B Duplicate Discounts

On January
27, 2020, the U.S. Government Accountability Office (GAO) released a report (the Report) assessing oversight
by the Department of Health and Human Services (HHS) of

31 Jan 2020

MedPAC Finds No Clear Link Between 340B Program and Increased Drug Spend

On January 17, 2020, the Medicare Payment Advisory
Commission (MedPAC) held its first meeting of the year, including a session
discussing a report requested by the House

23 Jan 2020

CMS Issues Informational Bulletin on State Duplicate Discount Practices

On January
8, 2020, the Centers for Medicare & Medicaid Services (CMS) issued an Informational Bulletin (Bulletin) outlining CMS’s view of
current “best practices” by states to

13 Jan 2020

DC Circuit Rules on 340B Medicare Advantage Discriminatory Reimbursement Case

The federal appeals court for the District of Columbia
Circuit recently ruled in favor of the Humana Medicare Advantage plan in a case
by a 340B covered

9 Jan 2020

Apexus Publishes Tool for Grantee Combined Purchasing and Distribution Requests

Last week, Apexus published a tool which states for the first time HRSA’s policy that all non-FQHC federal grantees are required to register each of

27 Nov 2019

AIR340B Releases Updated Study on Charity Care Rates at 340B Hospitals

Earlier this month, the Alliance
for Integrity and Reform of 340B (“AIR340B”), a national advocacy group funded
largely by pharmaceutical companies, released an update
to their previous reports

19 Nov 2019

New All-Agency Executive Orders May Undermine 340B Guidance

On October 9, 2019, the White House issued two executive orders with potential implications on HRSA’s ability to enforce its sub-regulatory guidance, including its patient

29 Oct 2019

OPA Reevaluates 340B Program Policies

340B Health reports that Capt. Krista Pedley, the Director of OPA, stated last week at the Medicaid Drug Rebate Conference that OPA is reevaluating its

3 Oct 2019
Top